What's the USC Ice Bucket Challenge? The viral video series, explained

Welcome to FTW Explains: A guide to catching up on and better understanding stuff going on in the world. You may have seen videos of people getting buckets of ice water dumped on their heads and had some deja vu, and also wondered what the heck is going on. That's OK! We're here to help.
That's right, the viral ice bucket challenge is back, and this time, it's for a different cause. When I started seeing these videos go viral again, I wondered if it was 2014, when we wrote a whole bunch of posts about celebrities and athletes getting water dumped on them.
But, nope! It's 2025! And it's back. Let's break down the whole thing:
It's simple. You turn on your phone to shoot a video and someone takes a bucket filled with ice and water and dumps it on your head. You then challenge other people to do it, and they do the same, and it goes on and on. Also, you include a link for donations on your social media post.
I was nominated for the USC Speak your mind ice bucket challenge!But on a serious note… please, if you ask for help — it doesn't make you weak.You are loved — and this world wouldn't be complete without you in it. 🤍 pic.twitter.com/q00ZpakHDg
— Angelina Marie Tamez (@AngelinaTamezTX) April 23, 2025
Back then, it was to bring awareness to ALS. This time, per USA TODAY: "The #SpeakYourMIND ice bucket challenge was created by students at the University of South Carolina's 'Mental Illness Needs Discussion' club, which first posted about the challenge on March 31."
Nearly $300,000 to Active Minds.
There have been discussions about how this is overshadowing the original cause, with the ALS Association posting this:
View this post on Instagram
A post shared by The ALS Association (@als)
I wouldn't call it a controversy, but there's discussion online.
This article originally appeared on For The Win: What's the USC Ice Bucket Challenge? Speak Your Mind videos go viral

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

28 minutes ago

• Yahoo

Dialysis Patient Citizens Applauds Texas Legislature for Passing Historic Bill Expanding Affordable Medigap Access for Dialysis and ALS Patients

AUSTIN, Texas, June 23, 2025 /PRNewswire/ -- House Bill 2516 has become public law, a significant victory for Texans living with End-Stage Renal Disease (ESRD), or kidney failure, and Amyotrophic Lateral Sclerosis (ALS). The legislation, championed by Representative Ryan Guillen (R-TX-31), received overwhelming bipartisan support in the Texas State Legislature, passing the House with a 133-4 vote and the Senate unanimously. The law guarantees that ESRD and ALS patients under the age of 65 can access affordable Medigap insurance. Specifically, Medigap Plans A, B, and D will be available at the same premium rate as for those age 65, while the remaining plans will be capped at no more than 200% of the age 65 rate. Now, younger Texans suffering from ESRD and ALS no longer need to worry about Medicare's gaps in coverage. "Today is a landmark moment for dialysis and ALS patients across Texas," said Andrew Conkling, Board President for Dialysis Patient Citizens (DPC). "This law brings long-overdue relief to individuals who, until now, faced Medigap premiums as high as $1,700 per month simply because they were under 65. It restores fairness and makes critical coverage accessible to those who need it most." Previously, under-65 ESRD and ALS patients in Texas were priced out of Medigap plans due to prohibitively high premiums. HB 2516 ensures those patients can finally afford the supplemental insurance they rely on to cover the gaps in Medicare. DPC Patient Ambassador and Texas resident Patricia Benavidez-Patel shared her compelling story in support of the bill, stating: "I've lived with dialysis, and I've lived with the constant fear of bills I can't afford. This law gives patients like me a real chance; it gives me not only a chance to survive, but a chance to live without fear of medical debt." In addition, former DPC board member Natalie Zuniga, who recently passed away, wrote a letter to the editor in defense of Medigap access. Her voice continues to echo during this victory for the dialysis community, which she so fiercely supported. Dialysis Patient Citizens thanks Representative Guillen for his steadfast leadership, Governor Abbott and the Texas Legislature, and all the patient advocates who helped make this victory possible. View original content to download multimedia: SOURCE Dialysis Patient Citizens Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Newsweek

4 hours ago

• Newsweek

Millennial's Theory on Why the Modern World Is So Stressful Goes Viral

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. With more people experiencing chronic stress-related health issues, one woman believes she has identified the root cause—and thousands are listening. Brittany Piper, a 36-year-old Somatic Experiencing® practitioner and author of Body-First Healing, has sparked widespread discussion online with her viral video dissecting why our lives today seem to be overwhelming the human nervous system. Posted on March 6, the video has more than 483,000 views and over 45,000 likes, resonating with viewers who say her theory helps explain their daily experiences of anxiety and burnout. "It is my personal and professional belief that the drastic rise we are seeing in chronic physical and mental illness can be attributed to this one thing," Piper said in the TikTok video, shared under @healwithbritt. "Basically, we have created a world that our nervous system no longer wants to live in." Speaking with Newsweek, Piper expanded on her message, saying the modern world simply is not built to accommodate the needs of the human nervous system. "Chronic survival states like fight, flight, shutdown, functional freeze and fawn are being activated—not just by traumatic events, but by the constant pressure, pace, and disconnection of our everyday lives," Piper said. Piper compared the nervous system to a security system, operating constantly in the background to assess for danger. She said that, when this system detects threat—real or perceived—it activates states like fight, flight, freeze, shutdown, or fawn. Repeated exposure to such stress, Piper added, can leave people stuck in these survival modes, with detrimental effects. "This further heightens the adrenalin and cortisol in your body, which then wreaks even more havoc on your mental and physical health," she told viewers. The stressors of the modern world, according to Piper, include political polarization; endless streams of catastrophic news on social media; workplace demands; environmental toxins; and widespread emotional suppression. The combination, she said, overwhelms the body's natural coping mechanisms, causing many of the chronic symptoms people experience today. From left: Brittany Piper speaks in a TikTok video; and speaks on stage at an event. From left: Brittany Piper speaks in a TikTok video; and speaks on stage at an event. @healwithbritt Piper is an international speaker with a combined following of over 600,000 across TikTok and Instagram. Her social-media content focuses on nervous system healing and somatic trauma work, emphasizing how people can support their health not by "fixing" themselves, but by listening to the body's signals. The popularity of her videos—and the hundreds of comments echoing their messages—suggests her theory has struck a chord with many. Viewers have shared their own experiences with chronic anxiety, fatigue, and illness, some expressing relief at finally hearing an explanation that connects the dots surrounding their symptoms and broader societal conditions. Piper described her post as a call to reevaluate how we interpret these debilitating conditions. "Many of the symptoms we face today at alarming rates—anxiety, fatigue, illness, pain—are not random symptoms, but the body's intelligent responses to overwhelm," Piper said. "Healing, then, begins with slowing down, coming back to the body, and learning to support the nervous system in releasing survival energy it was never able to complete." As an entry point for those unfamiliar with nervous system regulation, Piper recommends simple practices such as grounding through physical sensation. "Try feeling your feet on the floor, noticing your breath without changing it, or tuning into what feels good enough in your environment," Piper said. These actions, she added, can create an internal sense of safety that forms the foundation for deeper healing. Piper also cautioned against the cultural push toward hyperproductivity as a healing strategy. "Healing is less about doing more, and more about doing less, with more attunement," Piper added. Her approach to stress and trauma aligns with a growing body of work in the somatic therapy field, which focuses on how the body stores and processes stress. But Piper's viral reach has taken that message to a wider audience. The momentum around her videos reflects a broader shift in public dialogue around mental health, trauma, and somatic wellness. As more people look for explanations—and solutions—for why they feel so overwhelmed in their daily lives, Piper's message appears to offer both validation and a starting point for recovery. She added: "Once more capacity is built, deeper somatic work can unfold—like tracking subtle shifts in sensation, working with relational triggers, or titrating stored trauma with a practitioner." Is there a health issue that's worrying you? Let us know via health@ We can ask experts for advice, and your story could be featured on Newsweek.

Yahoo

5 hours ago

• Yahoo

Amyotrophic Lateral Sclerosis Treatment Market To Observe Growth at a CAGR of 6.1% by 2033

The global amyotrophic lateral sclerosis treatment market is undergoing gradual yet impactful transformation, driven by advancements in neurodegenerative disease research, gene-targeted therapies, and biomarkers innovation. Emerging therapeutic approaches, including antisense oligonucleotides and monoclonal antibodies, are enhancing precision treatment for genetically defined amyotrophic lateral sclerosis (ALS) subtypes, such as SOD1-linked ALS. Although ALS remains a rare condition, with an incidence of about 2 per 100,000 annually, it is receiving increased attention due to heightened awareness, improved diagnostic capabilities, and robust investment in R&D. The evolving treatment landscape is also benefiting from a growing emphasis on personalized medicine, which is reshaping disease management strategies for this devastating condition. Chicago, June 23, 2025 (GLOBE NEWSWIRE) -- The global amyotrophic lateral sclerosis treatment market is projected to grow from USD 724.5 million in 2024 to USD 1,234.5 million by 2033, reflecting a CAGR of 6.1% over the forecast period. This moderate yet steady expansion is supported by a rising aging population, advancements in disease-modifying therapies, and increasing prevalence rates. Although curative therapies remain elusive, the pipeline is increasingly populated with targeted investigational drugs, including small molecules, peptides, and biologics. Institutions and regulatory agencies are placing a growing focus on biomarker validation to accelerate clinical development and improve treatment outcomes. The recognition of biomarkers such as neurofilament light chain (NfL) as indicators of therapeutic response marks a pivotal step forward in streamlining ALS drug development. Download Free Sample Pages: The rising incidence of amyotrophic lateral sclerosis, particularly among adults aged 60 to 79, underscores the growing healthcare burden. In the U.S., the National ALS Registry estimated over 32,800 cases in 2022, with projections nearing 36,300 by 2030. The progressive nature and high mortality rate of ALS necessitate rapid intervention and proactive management. The predominance of sporadic ALS, comprising 90% of all cases, presents challenges in early detection and treatment targeting. Conversely, familial ALS, which accounts for roughly 10%, presents distinct genetic markers such as C9ORF72 and SOD1 mutations, offering a clearer path for precision therapies like Qalsody (Tofersen), which received FDA approval in 2023. Innovative drug approvals and clinical research are driving optimism. Treatments such as Riluzole, Edaravone, and more recently, gene-targeted agents like Tofersen and AMX0035, have brought incremental benefits. However, setbacks remains, for example; AMX0035 (Relyvrio) was withdrawn in 2024 following unsatisfactory phase III results. Nonetheless, therapeutic progress continues, with a growing number of trials exploring novel approaches, including stem cell-based interventions and gene editing technologies. The National Institutes of Health (NIH) has committed substantial funding, including a $25 million investment over five years, to accelerate ALS research and drug discovery efforts. Despite these advances, the amyotrophic lateral sclerosis treatment market continues to face notable challenges. The high cost of care, particularly in late-stage disease, imposes a significant financial burden. Treatment expenses in the U.S. can exceed $120,000 annually as the disease progresses, compounded by delayed diagnoses and complex care requirements. Furthermore, innovative gene therapies while promising carry a high price tags, as seen with Qalsody, which costs over $16,000 per 15 mL dose. Nevertheless, the amyotrophic lateral sclerosis treatment market holds promising potential, bolstered by biomarker innovation, gene-specific therapies, and a commitment to earlier diagnosis and intervention. With increasing efforts from academic research centers, pharmaceutical companies, and patient advocacy groups, the field is gradually shifting from symptomatic care toward disease-modifying approaches. As regulatory pathways evolve and precision medicine takes hold, the market is expected to offer more effective and personalized treatments, transforming the outlook for patients living with amyotrophic lateral sclerosis (ALS).Market Forecast (2033) USD 1,234.5 million CAGR 6.1% Top Driver Increasing Incidence of Amyotrophic Lateral Sclerosis (ALS) Among the Aging Population Top Trend Emerging Biomarkers in Amyotrophic Lateral Sclerosis Treatment Top Challenge Elevated Cost of Treating Amyotrophic Lateral Sclerosis (ALS) Biomarker Innovation: Advancing Diagnostic Precision and Accelerating ALS Therapeutics Rapid strides in biomarker research are transforming the treatment paradigm for amyotrophic lateral sclerosis (ALS), ushering in a new era of precision diagnostics and targeted therapeutic strategies. Historically constrained by delayed diagnoses and limited tools for tracking disease progression, the ALS field is now benefitting from biomarker technologies that enhance early detection, improve patient monitoring, and streamline the development of novel therapies. A pivotal breakthrough came in 2023 when the U.S. Food and Drug Administration (FDA) granted accelerated approval to Tofersen (Qalsody), establishing neurofilament light chain (NfL) as a qualified response biomarker. Clinical data revealed that reductions in NfL were indicative of slower neurodegeneration, validating its role in assessing treatment effectiveness. Building on this momentum, researchers are expanding their focus to identify other biomarkers, including abnormal forms of the TDP-43 protein, strongly associated with ALS pathology. Early detection of these proteins in cerebrospinal fluid or blood may enable real-time disease monitoring and inform more individualized treatment plans. Public-sector institutions are playing a key role in driving this progress. The National Institute of Neurological Disorders and Stroke (NINDS) is actively funding initiatives aimed at validating emerging biomarkers, particularly to shorten diagnostic timelines for patients with atypical or early-stage ALS. These efforts are critical to improving prognostic accuracy and tailoring therapeutic approaches to each patient's disease trajectory. As biomarker science continues to evolve, its integration into amyotrophic lateral sclerosis treatment and research is poised to deliver meaningful clinical and commercial impact. From optimizing trial design to facilitating faster regulatory approvals, biomarkers are redefining how amyotrophic lateral sclerosis (ALS) is diagnosed and managed moving the field closer to a future of earlier intervention, personalized care, and more effective therapies Global Amyotrophic Lateral Sclerosis Treatment Market: Regional Drivers Shaping the Future of Neuromuscular Care The global amyotrophic lateral sclerosis treatment market is segmented into North America, South America, Europe, Asia-Pacific, and the Middle East & Africa, with North America maintaining a dominant position. In the United States alone, an estimated 30,000 individuals are currently living with ALS, underscoring the urgent need for effective therapeutic options. The region leads in research and development, with most ALS medications receiving initial regulatory approval there. Key organizations like the ALS Association play a pivotal role in advancing treatment efforts, supporting a wide range of initiatives including grant-funded stem cell therapy programs. Enhanced insurance coverage further facilitates access to care, mitigating the financial burden of high treatment costs. Additionally, comprehensive support systems such as the ALS Network offer a wide array of services, from equipment loans and clinic access to benefit assistance, advocacy, and peer support groups, ensuring holistic care for patients and caregivers. Canada also plays an important role, with the Canadian Neuromuscular Disease Registry (CNDR) collecting nationwide clinical data to improve care standards and treatment accessibility. Building on the foundations established in North America, Europe has emerged as a strong contributor to ALS research and patient care. Collaborative efforts such as the ENCALS and TRICALS work with more than 60 centers across the continent to expand clinical trial availability, though currently, less than 5% of amyotrophic lateral sclerosis (ALS) patients in Europe participate in such studies. These efforts reflect a regional commitment to improving early access to experimental therapies and fostering cross-border collaboration in amyotrophic lateral sclerosis (ALS) care. The momentum continues to build in the Asia-Pacific region, where countries are increasingly investing in infrastructure and professional training. Japan is establishing dedicated multidisciplinary ALS centers, while emerging economies like India are making notable progress. In 2023/2024, over 550 Indian physicians received certification through Advanced Life Support (ALS) programs delivered in partnership with the European Resuscitation Council (ERC). These internationally accredited training initiatives are elevating standards of care and expanding clinical capacity across the region. While advancements are more gradual in the Middle East and Africa, the region is showing signs of long-term potential. With healthcare infrastructure and resources still in development, increasing attention to awareness-building, professional training, and international cooperation indicates a growing foundation for future market expansion. As these efforts mature, the region may play a more prominent role in the global amyotrophic lateral sclerosis treatment landscape. Modify Report as Per Requirements: Recent Advancements and Key Players in the Amyotrophic Lateral Sclerosis Treatment Market Several prominent players, including MediciNova, Mitsubishi Tanabe Pharma, Ionis Pharmaceuticals, Alector, Sanofi, ITF Pharma, Aquisitive Therapeutics, GSK, Denali Therapeutics, and BrainStorm Cell Therapeutics, are actively shaping the future of amyotrophic lateral sclerosis treatment through advancements in neurodegenerative research and synaptic regeneration. These companies are driving forward clinical development, regulatory progress, and therapeutic innovation in the amyotrophic lateral sclerosis treatment landscape. In a significant regulatory milestone, on June 3rd, 2025, Spinogenix announced that the European Medicines Agency (EMA) granted Orphan Drug Designation (ODD) to its lead candidate, SPG302, for the treatment of amyotrophic lateral sclerosis (ALS). This followed the recent completion of a Phase 2 clinical trial in Australia (NCT06903286), highlighting SPG302's potential as the first synaptic regenerative therapy for ALS. Further advancing ALS research, Transposon Therapeutics announced on May 28th, 2025, positive Phase 2 results for its investigational therapy TPN-101 in C9orf72-related ALS, showing reductions in neurofilament light chain (NfL) and interleukin-6 (IL-6) levels. TPN-101 is slated to enter the HEALEY ALS Platform Trial in Q4 2025, signaling continued momentum in adaptive trial designs. Similarly, on April 7th, 2025, Immunity Pharma reported positive Phase 2a clinical trial results for its investigational amyotrophic lateral sclerosis treatment, IPL344. The data showed that IPL344 significantly slowed the progression of ALS, as measured by the ALSFRS-R, by 58–64% compared to a matched control group from the PRO-ACT database. Additionally, treatment with IPL344 led to a 27% reduction in neurofilament light chain (NfL) levels after just two months, suggesting a potential disease-modifying effect. In a key regional development, the Japanese Ministry of Health, Labor and Welfare approved QALSODY in December 2024, expanding global access to this innovative therapy and underscoring Japan's regulatory support for amyotrophic lateral sclerosis treatments. These advancements underscore the rapid progress in amyotrophic lateral sclerosis drug development, driven by novel mechanisms of action and supportive global regulatory pathways. As leading companies continue to invest in clinical research and therapeutic innovation, the ALS treatment landscape is poised for transformation, offering renewed hope to patients worldwide. Future Outlook: Evolving Amyotrophic Lateral Sclerosis Treatments and the Rise of Regenerative Approaches The future of amyotrophic lateral sclerosis treatment is poised for significant change, with ongoing advancements in genetic therapies and an early promise in stem cell research. While current market leaders like Riluzole, Edaravone, and Qalsody continue to support disease management; high treatment costs and limited efficacy underscore the urgent need for more effective, accessible options. Stem cell therapies, particularly those involving mesenchymal stem cells (MSCs), remain in the research phase but are showing encouraging results. In 2025, DVCStem reported that MSCs may help delay onset, slow progression, and extend lifespan in ALS patients. Similarly, Mitsubishi Chemical's CL2020 completed Phase 2 trials with strong safety outcomes, reinforcing confidence in cell-based interventions. Looking ahead, the amyotrophic lateral sclerosis treatment landscape is expected to shift toward more personalized, regenerative, and combination-based approaches. As clinical trials advance and GMP-certified manufacturing expands, stem cell therapies may become a viable addition to standard care. By 2030, greater integration of genetic targeting, cellular therapies, and streamlined delivery models could redefine ALS management and offer new hope to patients worldwide. Key Competitors Medicinova Mitsubishi Tanabe Pharma Ionis Alector Sanofi ITF Pharma Aquisitive Therapuetice GSK Denali Therapuetics BrainStrom Segmentation of Amyotrophic Lateral Sclerosis Treatment Market By Treatment Type Medication Therapy Riluzole Radicava Qalsody Stem Cell Therapy By Distribution Channel Hospital & Clinics Pharmacies By Region North America South America Europe Asia-Pacific Middle East and Africa Have Questions? Reach Out Before Buying: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website: in to access your portfolio